Kiniksa Pharmaceuticals International (KNSA) Amortizatization of Intangibles (2018 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted Amortizatization of Intangibles of -$1.3 million for Q1 2026, down 240.0% on a QoQ basis from $930000.0 in Q4 2025, and down 410.59% year-over-year from $419204.5 in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's Amortizatization of Intangibles history runs 9 years deep, the most recent figure standing at -$1.3 million for Q1 2026.
- Quarterly Amortizatization of Intangibles fell 410.59% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$131000.0 (up 67.17% YoY) and the FY2025 annual result came in at $916000.0, up 307.71% from the prior year.
- Amortizatization of Intangibles was -$1.3 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $930000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.2 million in Q2 2023 and bottomed at -$1.4 million in Q3 2023.
- A 5-year average of $19000.0 and a median of $119000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Peak annual rise in Amortizatization of Intangibles reached 1615.79% in 2023, while the deepest fall reached 1310.92% in 2023.
- Kiniksa Pharmaceuticals International's Amortizatization of Intangibles stood at $203000.0 in 2022, then jumped by 45.81% to $296000.0 in 2023, then sank by 376.69% to -$819000.0 in 2024, then soared by 213.55% to $930000.0 in 2025, then plunged by 240.0% to -$1.3 million in 2026.
- Business Quant data shows KNSA's Amortizatization of Intangibles at -$1.3 million in Q1 2026, $930000.0 in Q4 2025, and -$603000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Kiniksa Pharmaceuticals International | 4.91 Bn | 4.45 Bn | 193.47 Mn | -1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.30 Mn |
| Mar 31, 2026 | -1.30 Mn |
| Dec 31, 2025 | 930,000.00 |
| Dec 31, 2025 | 930,000.00 |
| Sep 30, 2025 | -603,000.00 |
| Sep 30, 2025 | -603,000.00 |
| Jun 30, 2025 | 844,000.00 |
| Jun 30, 2025 | 844,000.00 |
| Mar 31, 2025 | -255,000.00 |
| Mar 31, 2025 | -255,000.00 |
| Dec 31, 2024 | -819,000.00 |
| Dec 31, 2024 | -819,000.00 |
| Sep 30, 2024 | 487,000.00 |
| Sep 30, 2024 | 487,000.00 |
| Jun 30, 2024 | 188,000.00 |
| Jun 30, 2024 | 188,000.00 |
| Mar 31, 2024 | -297,000.00 |
| Mar 31, 2024 | -297,000.00 |
| Dec 31, 2023 | 296,000.00 |
| Dec 31, 2023 | 296,000.00 |